Integra LifeSciences (NASDAQ:IART) Stock Rating Upgraded by BMO Capital Markets

Integra LifeSciences (NASDAQ:IART) was upgraded by equities researchers at BMO Capital Markets to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

IART has been the topic of several other research reports. Wall Street Zen upgraded shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Citigroup reiterated a “neutral” rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday. Truist Financial decreased their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Thursday, June 18th. Finally, Wells Fargo & Company raised their price target on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $17.17.

Integra LifeSciences Trading Up 6.3%

Shares of Integra LifeSciences stock opened at $18.39 on Wednesday. The stock has a market capitalization of $1.43 billion, a PE ratio of -2.85, a price-to-earnings-growth ratio of 1.20 and a beta of 1.22. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $18.92. The stock has a 50 day moving average price of $16.15 and a two-hundred day moving average price of $12.81. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same period in the prior year, the firm earned $0.41 earnings per share. Integra LifeSciences’s revenue for the quarter was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of Integra LifeSciences in the fourth quarter valued at about $4,722,000. Tejara Capital Ltd boosted its holdings in Integra LifeSciences by 42.6% during the fourth quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after purchasing an additional 51,300 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Integra LifeSciences by 15.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company’s stock worth $6,537,000 after purchasing an additional 71,950 shares during the last quarter. UBS Group AG grew its position in Integra LifeSciences by 211.7% in the 4th quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock worth $5,079,000 after purchasing an additional 277,745 shares in the last quarter. Finally, Systematic Financial Management LP grew its position in Integra LifeSciences by 4.5% in the 4th quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock worth $13,769,000 after purchasing an additional 48,094 shares in the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.